KDC-MN-359 – Kodiac biolabs

Plain-language summaryIntrigue 64 / 100

Bimagrumab is a humanized antibody against the activin receptor type II (the receptor that myostatin and related ligands bind) developed by Novartis and MorphoSys. By blocking the receptor at the cell surface, it prevents engagement by myostatin, activin A, and GDF-11 in one shot. It has been investigated for sporadic inclusion body myositis, sarcopenia, and (more recently) obesity-related muscle preservation, where it has produced meaningful fat loss alongside muscle gain in early trials. Most trials have not met primary endpoints in muscle disease populations, but the obesity application has revived clinical interest. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNovel, promising

65/100

Receptor-level ActRII blocker with an unusual fat-loss plus muscle-gain profile that stands apart in the GLP-1 era

Look, the myostatin inhibitor space has a graveyard in it. ACE-031 was stopped for safety. Stamulumab showed muscle signal in Becker but couldnt replicate it cleanly. The whole class got written off by a lot of investigators around 2015. Bimagrumab is the compound that survived that shakeout, and the reason it survived is that it’s doing something structurally different from its predecessors.

Most myostatin pathway inhibitors are ligand traps or single-ligand antibodies. Bimagrumab binds ActRIIA and ActRIIB directly at the receptor level, which means it blocks myostatin, activin A, and GDF-11 in one shot. That’s not a marginal technical distinction. Activin A in particular is now understood to be a co-driver of muscle wasting in several contexts, and blocking it alongside myostatin gives a broader suppression of the pathway than a selective antibody can achieve. That’s the mechanism we find genuinely interesting here.

The RESILIENT trial in sporadic inclusion body myositis showed lean mass gains. The sarcopenia work showed lean mass gains. Those are real, replicated signals in two different wasting contexts. But the thing that really sharpened our interest is the 2020 BIM-T2D phase 2 data, where bimagrumab produced roughly 21 percent fat mass reduction alongside muscle preservation in obese patients with type 2 diabetes. That combination profile is unusual. Most pharmacological interventions that drive fat loss also drive some lean mass loss. Bimagrumab’s direction of effect is inverted on the muscle side, and that matters enormously now that GLP-1 agonists are being criticized for the lean mass loss they produce during rapid weight reduction.

Honestly, the timing here matters as much as the mechanism. If this data had come out in 2014 it would have been interesting but not urgent. Coming out in 2020 and being developed further in parallel with semaglutide and tirzepatide’s rise, the muscle-preserving fat loss profile is suddenly one of the more clinically relevant compound profiles in the space. Novartis has continued development, and there are combination-with-GLP-1 trials being discussed or initiated.

What we dont like: the evidence base is still mostly phase 2. The fat mass reduction finding needs phase 3 confirmation. And the underlying ActRII biology, while elegant, is not fully de-risked. Off-target effects on reproductive biology and bone are a real pharmacology concern at this receptor level. As a research probe for receptor-level myostatin pathway biology, it’s genuinely the cleanest tool available. As a compound, its overall profile is strong enough to warrant serious attention but not yet the finished story.

Novelty: 62
Mechanism promise: 73
In-category differentiation: 65
Evidence quality: 60
Translational signal: 65
Research bench value: 60

Rationale Bimagrumab scores well on mechanism and differentiation because its ActRII receptor-level blockade is mechanistically distinct from failed ligand traps and selective myostatin antibodies, and the 2020 BIM-T2D phase 2 data showing ~21% fat mass reduction with concurrent lean mass gain is genuinely unusual. Novelty is held down somewhat because the compound has been in clinical development since roughly 2013; the obesity angle is fresh but the underlying biology is a decade old.

Anti-activin receptor type II monoclonal antibody

A humanized monoclonal antibody against activin receptor type II; investigated for sarcopenia, sIBM, and obesity-related muscle preservation.

Abstract

Bimagrumab (BYM338; humanized IgG1 monoclonal antibody; molecular weight approximately 145 kDa) is a humanized monoclonal antibody against activin receptor type II (ActRII), developed at MorphoSys and Novartis. The compound binds ActRIIA and ActRIIB receptors on the cell surface, blocking access by myostatin, activin A, and GDF-11; the receptor-level blockade is mechanistically distinct from ligand traps (ACE-031) and from selective myostatin antibodies (stamulumab). Phase 2 trials in sporadic inclusion body myositis (RESILIENT) and sarcopenia demonstrated muscle mass increases. The compound generated substantial interest in 2020 after a phase 2 trial in obesity with type 2 diabetes (BIM-T2D) showed approximately 21 percent reduction in fat mass with concurrent muscle preservation, an unusual profile that has subsequently driven obesity-related development. Used as a research probe for receptor-level myostatin pathway inhibition.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-359Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-359

Bimagrumab

Abstract

Read the full monograph